Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorPublished on 21.12.2021
N. Berger, M. Kumar Muthyala, D. Sarma, K. Rustler, T. Bruckdorfer, R. Zitterbart
Chimica Oggi 2021; 39(6): 38-41
Abstract: With a remarkable amount of peptide therapeutics already on the market and many more to come, there is an ongoing need to improve manufacturing scale and efficiency for a sustainable, global supply. Especially the trend towards longer and modified peptides challenges manufacturers to meet quality specifications and scale requirements. For example, more orally available peptide drugs will enter the market requiring worldwide supply in ton-scale. Herein, we introduce an innovative route for the chemical synthesis combined with orthogonal Peptide Easy Clean (PEC)-purification of the blockbuster peptide drug liraglutide, a fatty acid-modified peptide. We demonstrate easy and seamless upscaling to gram-scale, rendering this manufacturing route an attractive way to produce complex peptides for R&D and potentially in multi-kg and ton scales. PEC-assisted manufacturing can significantly save downstream costs due to high productivity, high yield, and low solvent consumption.